A pharmaceutical composition comprising 7 mg to 350 mg of a compound according to the following Formula , an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof wherein R is selected from the group consisting of COOR 6 , CONR 7 R 8 , tetrazolyl, SO 2 NR 7 R 8 , C 1-6 alkyl, SO 2 -C 1-6 alkyl and H, with R 6 independently selected from the group consisting of H or C 1-6 alkyl, and R 7 and R 8 independently from each other selected from the group consisting of H, C 1-6 alkyl, halo-C 1-6 alkyl, C 1-6 alkylene-R 9 , SO 2 -C 1-6 alkyl, wherein R 9 is selected from the group consisting of COOH, OH and SO 3 H; A is selected from the group consisting of phenyl, pyridyl, pyrimidyl, pyrazolyl, indolyl, thienyl, benzothienyl, indazolyl, benzisoxazolyl, benzofuranyl, benzotriazolyl, furanyl, benzothiazolyl, thiazolyl, oxadiazolyl, each optionally substituted with one or two groups independently selected from the group consisting of OH, O-C 1-6 alkyl, O-halo-C 1-6 alkyl, C 1-6 alkyl, halo-C 1-6 alkyl, C 3-6 cycloalkyl and halogen; Q is selected from the group consisting of phenyl, pyridyl, thiazolyl, thiophenyl, pyrimidyl, each optionally substituted with one or two groups independently selected from the group consisting of C 1-6 alkyl, halo-C 1-6 alkyl, halogen and CF 3 ; Y is selected from N or CH; Z is selected from wherein X = CH, N, NO; R 1 is selected from the group consisting of hydrogen, C 1-3 alkyl, C 3-6 cylcoalkyl, C 4-5 alkylcycloalkyl, wherein C 1-3 alkyl is optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxy or C 1-6 alkoxy; R 2 and R 3 are independently selected from the group consisting of hydrogen, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 haloalkoxy and halogen, and a pharmaceutically acceptable carrier, for use as a total daily dose for a 70 kg adult human. R is selected from the group consisting of COOR 6 , CONR 7 R 8 , tetrazolyl, SO 2 NR 7 R 8 , C 1-6 alkyl, SO 2 -C 1-6 alkyl and H, with R 6 independently selected from the group consisting of H or C 1-6 alkyl, and R 7 and R 8 independently from each other selected from the group consisting of H, C 1-6 alkyl, halo-C 1-6 alkyl, C 1-6 alkylene-R 9 , SO 2 -C 1-6 alkyl, wherein R 9 is selected from the group consisting of COOH, OH and SO 3 H; A is selected from the group consisting of phenyl, pyridyl, pyrimidyl, pyrazolyl, indolyl, thienyl, benzothienyl, indazolyl, benzisoxazolyl, benzofuranyl, benzotriazolyl, furanyl, benzothiazolyl, thiazolyl, oxadiazolyl, each optionally substituted with one or two groups independently selected from the group consisting of OH, O-C 1-6 alkyl, O-halo-C 1-6 alkyl, C 1-6 alkyl, halo-C 1-6 alkyl, C 3-6 cycloalkyl and halogen; Q is selected from the group consisting of phenyl, pyridyl, thiazolyl, thiophenyl, pyrimidyl, each optionally substituted with one or two groups independently selected from the group consisting of C 1-6 alkyl, halo-C 1-6 alkyl, halogen and CF 3 ; Y is selected from N or CH; Z is selected from wherein X = CH, N, NO; R 1 is selected from the group consisting of hydrogen, C 1-3 alkyl, C 3-6 cylcoalkyl, C 4-5 alkylcycloalkyl, wherein C 1-3 alkyl is optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxy or C 1-6 alkoxy; R 2 and R 3 are independently selected from the group consisting of hydrogen, C 1-3 alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 haloalkoxy and halogen, and a pharmaceutically acceptable carrier, for use as a total daily dose for a 70 kg adult human. <EOS>